EVO

Evotec SE ADR

EVO, USA

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

https://www.evotec.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EVO
stock
EVO

Barclays Sees Weak Outlook for Evolution, Downgrades Stock Two Notches - BN marketscreener.com

Read more →
EVO
stock
EVO

(EVO) Market Dynamics and Trading Signals (EVO:CA) news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$5.5142

Analyst Picks

Strong Buy

1

Buy

3

Hold

1

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.34

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-5.38 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-2.43 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-53.55 %

Low 5%

High 15%

Debt to Equity

-

Very Low

1.22

Low 1

High 0.3

Investors

* Institutions hold a combined 3.52% of the total shares of Evotec SE ADR

1.

Mubadala Investment Company PJSC

(1.2944%)

since

2025/06/30

2.

BlackRock Inc

(0.3773%)

since

2025/06/30

3.

iShares Biotechnology ETF

(0.3546%)

since

2025/08/31

4.

Wellington Management Company LLP

(0.3394%)

since

2025/06/30

5.

DCF Advisers, LLC

(0.3138%)

since

2025/06/30

6.

Morgan Stanley - Brokerage Accounts

(0.1085%)

since

2025/06/30

7.

LVIP Wellington SMID Cap Value Std

(0.1019%)

since

2025/06/30

8.

WCM Investment Management

(0.0839%)

since

2025/06/30

9.

VALIC Company I Mid Cap Value

(0.0778%)

since

2025/07/31

10.

Pitcairn Co

(0.0735%)

since

2025/06/30

11.

Pitcairn Financial Group Inc

(0.0735%)

since

2025/06/30

12.

EQ/Mid Cap Value Managed Volatil IB

(0.0731%)

since

2025/07/31

13.

Wellington Smid Opportunistic Value

(0.0482%)

since

2025/06/30

14.

Mid Cap Value (sub-advised by WM) SP

(0.0482%)

since

2025/06/30

15.

WCM Focused International Equity

(0.0405%)

since

2025/06/30

16.

Envestnet Asset Management Inc

(0.0258%)

since

2025/06/30

17.

Marshall Wace Asset Management Ltd

(0.0113%)

since

2025/06/30

18.

ABC arbitrage SA

(0.011%)

since

2025/06/30

19.

LPL Financial Corp

(0.0107%)

since

2025/06/30

20.

Wellington CIF II SMID Opp Value S1

(0.0106%)

since

2025/06/30

21.

Citadel Advisors Llc

(0.0095%)

since

2025/06/30

22.

SNOWDEN CAPITAL ADVISORS LLC

(0.0082%)

since

2025/06/30

23.

Bank of America Corp

(0.0058%)

since

2025/06/30

24.

Commonwealth Equity Services Inc

(0.0051%)

since

2025/06/30

25.

XTX Topco Ltd

(0.0044%)

since

2025/06/30

26.

UMB Bank NA

(0.0037%)

since

2025/06/30

27.

Css LLC

(0.0034%)

since

2025/06/30

28.

BNP Paribas Arbitrage, SA

(0.0034%)

since

2025/06/30

29.

JHancock Seaport Long/Short R6

(0.0025%)

since

2025/02/28

30.

Fidelity Nasdaq Composite Index

(0.0007%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

0.0664

Latest Release

Date

2025-09-30

EPS Actual

-0.0469

EPS Estimate

-0.0778

EPS Difference

0.0309

Surprise Percent

39.7172%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.